In a readout of data from the phase 2 BNT111-01 trial (NCT04526899) presented at the 2025 European Society for Medical ...

The combination of pembrolizumab (Keytruda) and lenvatinib (Lenvima) elicited promising progression-free survival (PFS) outcomes in patients with uveal melanoma who were both HLA-A*02:01–negative and ...

Sacituzumab tirumotecan (sac-TMT) significantly improved progression-free survival compared to chemotherapy in HR-positive, HER2-negative breast cancer patients. Sacituzumab tirumotecan significantly ...

T-DXd significantly improved IDFS and reduced the risk of invasive disease or death by 53% compared to T-DM1 in high-risk, HER2-positive breast cancer patients. The trial demonstrated superior ...

Tiragolumab plus atezolizumab did not improve progression-free survival compared to durvalumab in stage III NSCLC patients post-cCRT. Median progression-free survival and overall survival were similar ...

ITM-11 significantly improved PFS and OS compared to everolimus in GEP-NET patients, meeting primary and secondary endpoints. Subgroup analyses showed ITM-11's efficacy across tumor grades and prior ...

Tarlatamab combined with chemoimmunotherapy achieved a 71% objective response rate in ES-SCLC, with a median response duration of 11 months. The safety profile was manageable, with grade 3 or 4 ...

Invikafusp alfa demonstrated significant antitumor activity in TMB-H and MSI-H tumors resistant to immune checkpoint blockade, with ORRs ranging from 20.5% to 33.3%. The trial's safety profile was ...

Previously, the FDA granted accelerated approval to tarlatamab as a treatment for patients with extensive-stage SCLC following progression on prior platinum-based chemotherapy in May 2024. 2 ...

XTR008 significantly improved PFS, ORR, and quality of life compared to octreotide LAR in SSTR-positive GEP-NETs. XTR008 therapy shows significant benefits in treating GEP-NETs, enhancing survival ...

Fruquintinib plus sintilimab significantly improved PFS in advanced RCC patients compared to axitinib or everolimus, with a median PFS of 22.21 months versus 6.90 months. The combination therapy ...

The MANEUVER trial was a global, randomized, double-blind, placebo-controlled study evaluating pimicotinib in unresectable TGCT patients. Pimicotinib shows promising long-term efficacy in treating ...